Supplementary Methods, Tables S1 - S2, S4, Figures S1 - S11 from Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy

Autor: Charles Swanton, George B. Hanna, Daniel Hochhauser, Nik Matthews, Sharmin Begum, Jennifer Biggs, Benjamin Phillimore, Andrew Rowan, Stuart Horswell, Richard Mitter, Max Salm, Nima Abbassi-Ghadi, Sacheen Kumar, Nicholas McGranahan, Thomas B.K. Watkins, Nicolai J. Birkbak, Gareth A. Wilson, Nirupa Murugaesu

Supplementary Materials and Methods Supplementary Table S1 - Sequencing coverage for tumor regions and germline samples Supplementary Table S2 - Clinical characteristics of patients with EAC Supplementary Table S4 - Annotation of chromosomal segments

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e21c40daeeff76e149cc62995df1e1c5
https://doi.org/10.1158/2159-8290.22531587

Data from CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma

Autor: John D. Kelly, Asif Muneer, Tyson V. Sharp, Tim Fenton, Stephan Beck, Tom Powles, Gareth A. Wilson, Charles Jameson, Alex Freeman, Simon Rodney, Wei Shen Tan, Peter R. Malone, Raj Nigam, Muhammad Saqib, Manit Arya, Kunal Shah, Patricia de Winter, Ankur Chakravarthy, Daniel C. Worth, Andrew Feber

Other than an association with HPV infection, little is known about the genetic alterations determining the development of penile cancer. Although penile cancer is rare in the developed world, it presents a significant burden in developing countries.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::216f52586a881f6887a26d4372aad33a
https://doi.org/10.1158/0008-5472.c.6508209.v1

Supplementary Table 1 and Supplementary Figures 1 through 6 from CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma

Autor: John D. Kelly, Asif Muneer, Tyson V. Sharp, Tim Fenton, Stephan Beck, Tom Powles, Gareth A. Wilson, Charles Jameson, Alex Freeman, Simon Rodney, Wei Shen Tan, Peter R. Malone, Raj Nigam, Muhammad Saqib, Manit Arya, Kunal Shah, Patricia de Winter, Ankur Chakravarthy, Daniel C. Worth, Andrew Feber

Supplementary Table 1. A)Patient details for Fresh Frozen test cohort, B) Patient details for validation cohort. Supplementary Figure 1. APOBEC mutation fraction of across multiple cancer types. Supplementary Figure 2. DNA methylation. Supplementary

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::699ead6d2c936e199f3310310b0271a9
https://doi.org/10.1158/0008-5472.22411374

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Autor: Saba Ferdous, Charles Swanton, Francesca Chemi, Chang Sik Kim, Selvaraju Veeriah, Ged Brady, Sakshi Gulati, Deborah J. Burt, Mariam Jamal-Hanjani, Fiona H Blackhall, Daniel Slane-Tan, Nicholas McGranahan, Jackie Pierce, Marek Dynowski, Crispin J. Miller, Barbara Mesquita, Dominic G. Rothwell, Cong Zhou, David Allan Moore, Simon P. Pearce, Fabio Gomes, Philip A.J. Crosbie, Jonathan Tugwood, Nicolai Juul Birkbak, R. Shah, Gareth A. Wilson, Christopher Abbosh, Sophia Ward, Maise Al Bakir, Allan Hackshaw, Crispin T. Hiley, Caroline Dive, Dhruva Biswas, Yvonne Summers

Publikováno v: Chemi, F, Rothwell, D G, McGranahan, N, Gulati, S, Abbosh, C, Pearce, S P, Zhou, C, Wilson, G A, Jamal-Hanjani, M, Birkbak, N, Pierce, J, Kim, C S, Ferdous, S, Burt, D J, Slane-Tan, D, Gomes, F, Moore, D, Shah, R, Al Bakir, M, Hiley, C, Veeriah, S, Summers, Y, Crosbie, P, Ward, S, Mesquita, B, Dynowski, M, Biswas, D, Tugwood, J, Blackhall, F, Miller, C, Hackshaw, A, Brady, G, Swanton, C, Dive, C & TRACERx Consortium 2019, ' Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse ', Nature Medicine, vol. 25, no. 10, pp. 1534-1539 . https://doi.org/10.1038/s41591-019-0593-1
TRACERx Consortium 2019, ' Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse ', Nature Medicine, vol. 25, no. 10, pp. 1534-1539 . https://doi.org/10.1038/s41591-019-0593-1

Approximately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who undergo surgery with curative intent will relapse within 5 years1,2. Detection of circulating tumor cells (CTCs) at the time of surgery may represent a tool to iden

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d6ddd0b6c3e7f59bde65bfbe961685
https://doi.org/10.1038/s41591-019-0593-1

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

Autor: Jin-Li Luo, Min Zhang, Edward J. Hollox, Catrin Pritchard, Charlotte Poile, Charles Swanton, Luke Martinson, Aleksandra Bzura, John Le Quesne, Nathaniel Kuse, Frank Dudbridge, Essa Y. Baitei, Tamihiro Kamata, Gareth A. Wilson, Cathy Richards, Aarti Gaba, Dean A. Fennell, Pan De Philip Zhang, Amrita Bajaj, Annabel J. Sharkey, David A. Waller, Michael Sheaff, Lee Brannan, Maymun Jama, Gareth Griffiths, Sara Busacca, Joanna Działo, Qianqian Sun, Apostolos Nakas, Hongji Yang, James Harber, Alan G. Dawson, Jacqui Shaw, Peter Wells-Jordan

Publikováno v: Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)

Malignant Pleural Mesothelioma (MPM) is typically diagnosed 20–50 years after exposure to asbestos and evolves along an unknown evolutionary trajectory. To elucidate this path, we conducted multi-regional exome sequencing of 90 tumour samples from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bada8a87126c661758876f8f37a1ce1
https://doi.org/10.1038/s41467-021-21798-w